Yuichiro� Doki

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Ken Kato, Byoung Chul Cho, Masanobu Takahashi et al. · The Lancet Oncology · 2019 · 1.2K citations · Full text

Esophageal Cancer, Gastrointestinal Oncology, Medicine +7

Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers

Takuro Saito, Hiroyoshi Nishikawa, Hisashi Wada et al. · Nature Medicine · 2016 · 861 citations

Tumor Biology, Colorectal Cancers, Medicine +8

Reprogramming of Mouse and Human Cells to Pluripotency Using Mature MicroRNAs

Norikatsu Miyoshi, Hideshi Ishii, Hiroaki Nagano et al. · Cell stem cell · 2011 · 751 citations · Full text

Induced Pluripotent Stem Cell, Developmental Biology, Human Cells +9

CD13 is a therapeutic target in human liver cancer stem cells

Naotsugu Haraguchi, Hideshi Ishii, Koshi Mimori et al. · Journal of Clinical Investigation · 2010 · 602 citations · Full text

Cell Therapy, Cd13 Inhibitor, Immunology +17

Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2

Yuko Kitagawa, Takashi Uno, Tsuneo Oyama et al. · Esophagus · 2018 · 585 citations · Full text